KLK3 and prostate carcinoma: Koerber et al. [33] assessed the clinical outcome of [68 Ga]PSMA-11 PET/CT-guided radiotherapy to selected metastases in 86 patients with recurrent oligometastatic prostate carcinoma, with 61.9% of patients receiving concomitant ADT, and reported a > 50% PSA response in 73.3% of the cohort.